Navigation Links
New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
Date:4/19/2009

SYDNEY, April 20 /PRNewswire/ -- Australian medical research company Immune System Therapeutics Ltd (IST) has launched a clinical trial to test its breakthrough treatment for terminal blood cancers.

IST has genetically engineered an antibody drug that binds specifically to a target protein found on the surface of some blood cancer cells. Laboratory studies, using cells taken from patients with a type of blood cancer called multiple myeloma, have shown that the antibody works with the human immune system to induce death of the cancer cells. It is anticipated that the antibody will potentially reduce the number of cancerous cells in multiple myeloma patients and improve patient health and wellbeing.

IST has commenced a Phase 1 trial in patients with multiple myeloma and to date six patients have been treated at The Alfred Hospital in Melbourne under the supervision of Dr. Andrew Spencer. Results so far indicate that the antibody has no side effects and final results are expected later this year.

IST's Director of Clinical Development, Dr. Rosanne Dunn, said in order to maintain the recruitment momentum, the Company is seeking to enroll another nine multiple myeloma patients with the kappa form of the disease to be treated over the next few months.

"We are very pleased that the antibody drug is performing as expected with patients suffering no adverse effects. Although this is very rare in cancer treatment it is an indication that the antibody specifically targets cancer cells and not normal cells," she said.

IST's CEO, Mr. Alan Liddle, said multiple myeloma is a very debilitating terminal disease, with an estimated patient population of over 100,000 worldwide.

He said IST is undertaking further pre-clinical work on other blood cancers and diseases that are associated with the same target and could potentially be treated with the same antibody drug.

"If we continue to be successful in the current multiple myeloma trial, we expect to be able to move into other types of blood cancer in the coming year," Mr. Liddle said.

    For further information, please contact:

    Dr. Rosanne Dunn - +61 2 9514 4060
    Alan Liddle - +61 2 9514 7437
    Immune System Therapeutics
    www.ISTL.com.au


'/>"/>
SOURCE Immune System Therapeutics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Australian Technology: Detecting Breast Cancer With Hair
2. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
3. Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
4. Major deCODE-led Study Underscores Role of the Brain in Obesity
5. Isogen Launches Major New Facility to Address Global Biopharma Demand
6. MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
7. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
8. Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of Mr. C Causes Major Interest in the Scientific Community
9. First Ever Study on Alzheimers Disease Treatment in Hispanics Presented at Major Medical Meeting
10. Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Divoti USA will engrave and process all non-coated stainless ... FDA requirements, which stipulates new criteria regarding medical device manufacture and ... ID jewelry such as Medical ID Bracelets, can rest assured that ... the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving process with ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: ... that developed an innovative way to use nonlinear optical ... delivery of new drugs. ... Dermatology Conference will show how researchers from BioPharmX and ... Medical School used a suite of imaging techniques in ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
Breaking Medicine Technology:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
Breaking Medicine News(10 mins):